Interview: Ellson Chen, President & CEO, Vita Genomics, Taiwan
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Address: 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan
Tel: (+886) 2-8976-9123
Web: http://www.vitagenomics.com/
Vita Genomics, founded in March 2001, has established its headquarter in Taiwan, a marketing office in California, USA, and a wholly owned subsidiary GeneCore in Shanghai, China. Vita Genomics has envisioned itself to be an important player in the healthcare industry by offering advanced and targeted molecular diagnostic products and services, providing more efficient and safer medical solutions, improving the drug development process, and lowering the overall healthcare cost through the pharmacogenomics approaches.Vita Genomics has already built up strong relationships with research institutions and medical organizations throughout Taiwan and China. We are constantly looking for pharmaceutical partners who can benefit from identifying patients for drug responsiveness prior to treatments, partners who would fund expanded pharmacogenomics studies that will enable us to validate the responsiveness of all significant genotypes, and partners who would co-develop DNA-based molecular diagnostic products. Vita Genomics is an active participant in modernizing Taiwan healthcare system. We are establishing the infrastructure needed to add the molecular profile information to the healthcare integrated circuit (IC) card. This is a first step in creating personalized medicine in the future. In addition, Vita Genomics can act as the conduit between the western world and China because we have already established a beachhead in Shanghai.
Vita Genomics follows the high standards of US FDA guidelines in collecting samples in conducting research and clinical studies.Vita Genomics concentrates on the elucidation of the genes and pathways involved in various diseases and on the drug responsiveness of patients in an attempt to improve the healthcare system.
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Yu-Ih Hou, mayor of New Taipei City, introduces the city and highlights its key competitive advantages and strategic direction of growth as Taiwan’s top economic and cultural destination. Over…
Wei-Hong Tseng, founder and chairman of PharmaCore Biotech, introduces the specialized CDMO and its unique capacities to produce high value-added products. As a leading service provider in Taiwan, Tseng goes…
Carol Cheng, chief operating officer of the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), gives an update on the current condition of Taiwan’s biopharma environment and speaks about the country’s innovative…
Bach Chen, CEO of Maisense, highlights the innovative new solutions that the company has created in cardiovascular preventative medicine. Their advanced technology, Freescan, is providing an advanced solution to prevent…
Alan Tsai, general manager, and Carson Chen, chief technology officer of iXensor introduce the startup as an innovative player in the point-of-care diagnostics and digital health space. They jointly discuss…
Dr Jan-Mou Lee, founder of FullHope Biomedical, shares his story of how he came to establish his company after a realization about the loss of impact that occurs when critical…
Arthur Kadurin, CEO of Insilico Medicine Taiwan, tells us how artificial intelligence can change drug discovery process using the innovative generative adversarial networks (GANs) approach. AI is the future…
Ed Deng, co-founder and CEO of Health2Sync, a digital health startup specialized in diabetes management, shares how the application is revolutionizing the ability of patients to take control of the…
Tsung-Tsong Wu, minister without portfolio, offers insights into the current state of Taiwan’s biomedical landscape three years after the administration’s Biomedical Industry Innovation Program was put into place to bolster…
Dr Tse Wen Chang, founder of Immunwork, gives an update on the preclinical development process of the company’s revolutionary T-E pharmaceutical products and goes on to give his expert insights…
Dr James Chih-Hsin Yang, director of National Taiwan University Hospital’s department of oncology, speaks about oncology in Taiwan and the role that the NTU network plays in the island’s oncology…
Rongjin Lin, chairman of Center Ventures and Center Laboratories shares his story of how he revived Center Laboratories from the brink of bankruptcy and repositioned the pharmaceutical company to become…
See our Cookie Privacy Policy Here